Filing Flows › Theravance Biopharma (TBPH) › Recalls, complaints & regulation
Theravance Biopharma (TBPH): clinical trials
Theravance Biopharma (TBPH) beyond its filings: 1 active clinical trial.
Theravance Biopharma's latest quarter
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Theravance Biopharma have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.